替罗非班在急性心肌梗死介入治疗中的临床研究(1)
 |
| 第1页 |
参见附件(320KB，3页)。
[摘要] 目的：观察在急性心肌梗死(AMI)患者经皮行冠状动脉介入治疗(PCI)时替罗非班的有效性及安全性。方法：60例已确诊的AMI患者PCI术前随机分为替罗非班组(替罗非班+PCI，30例)和对照组(常规PCI，30例)。替罗非班组PCI术静脉应用替罗非班+半量肝素，对照组仅应用全量肝素治疗，观察两组PCI术后即刻梗死相关动脉(IRA)TMP(TIMI myocardial perfusion) 血流情况，24 h及30 d主要不良心脏事件(MACE)发生率，出血事件发生率。结果：替罗非班组TMP3级为96.7%(29/30)，对照组为 80.0%(24/30)(P0.05)。结论：替罗非班可安全用于急性心肌梗死介入治疗中，改善心肌组织再灌注，减少不良心脏事件，疗效优于常规治疗。
[关键词] 替罗非班；急性心肌梗死；冠状动脉介入治疗；有效性；安全性
[中图分类号] R541[文献标识码]A [文章编号]1673-7210(2008)05(b)-011-03
Efficacy and safety of tirofiban for percutancous coronary intervention in patients with acute myocardial infarction
WANG Xiao-ping, QIN Ying
(Department of Cardiology, Shenzhou Hospital of Shenyang Medical College, Shenyang 100002，China)
[Abstract] Objective:To evaluate the efficacy and safety of tirofiban for percutaneous coronary intervention in patients with acute myocardial infarction. Methods: 60 patients diagnosed AMI were randomly divided into tirofiban group(n=30) who received tirofiban and half-heparin dose,andthe control group(n=30),who were treated by full dose heparin during PCI. The coronary TMP flow of IRA after PCI，major adverse cardiac events (MACE) rates within 24 hours and 30 days, bleeding rates were analyzed and compared between the two groups. Results:Three degree TIMI myocardial perfusion oftirofiban group was 96.7%(29/30),but thecontrol group was 80.0%(24/30)(P
您现在查看是摘要介绍页，详见PDF附件(320KB，3页)。